Select region:

Clinical trials located in


Leiden city is located in Netherlands. Currently, 20 clinical trials are being conducted in this city.

Leiden, nestled in the Netherlands, is renowned for its rich history and cultural heritage. Birthplace of the famous painter Rembrandt, this city is a treasure trove of historical buildings, ancient alleyways, and charming canals. Leiden is also home to the oldest university in the country, the University of Leiden, established in 1575, which has fostered numerous notable scholars. The city played a pivotal role during the Dutch Golden Age, becoming a center for science, arts, and exploration. Its botanical garden, Hortus Botanicus, established in 1590, is one of the oldest in the world, showcasing Leiden’s long-standing tradition of botanical research.

  • CT-EU-00114817

    Discovering the best treatments for prolactinoma: comparison of treatment strategies — surgery and drug therapy

    The study aims to look at different treatments for prolactinoma, a type of cancer that produces the hormone prolactin in the pituitary gland. This test is designed to determine whether you should undergo immediate nasal surgery (endoscopic transsphenoidal resection of prolactinoma) or after short-term (4-6 months) or long-term (over 2 years) treatment with drugs called dopamine agonists. Typical treatment involves taking dopamine agonists such as cabergoline, bromocriptine or quinagolide, which are pills that help control the levels of prolactin in the body. These drugs are the first-line treatment, and surgery is usually considered if the drug does not work or if someone cannot tolerate it.

    The main goal of this study is to see how different treatment approaches affect the quality of life and the chances of improvement, which is called remission. Remission means that your prolactin levels have returned to normal without the need for medication for at least 3 months or, if you are a woman, that you can get pregnant without medication during that time. The study will also take into account other important factors such as the effectiveness of disease control, possible recurrence, improvement of symptoms, changes in tumor size on MRI images, pituitary gland function, side effects of treatment, the overall impact of the disease on the patient’s life and how cost-effective these treatments are treatment methods.

    This study is being conducted in multiple centers, which means that it involves cooperation between several hospitals or clinics. It is designed to help doctors and patients understand the best ways to treat prolactinoma, and its goal is to improve the lives of people affected by this disease.

  • Study on the effectiveness and safety of BBP-418 for Limb Girdle Muscular Dystrophy 2I patients

    This clinical trial is focused on a new treatment option for individuals diagnosed with Limb Girdle Muscular Dystrophy 2I (LGMD2I). This study is designed to explore the efficacy and safety of a medication called BBP-418 (Ribitol), which is administered as an oral solution. The medication is in the form of granules that are mixed with water to create a drinkable solution.

    The aim is to include participants aged 12 to 60 years old, covering a wide range of individuals affected by LGMD2I. Throughout a 36-month period, the study will closely monitor changes in the muscle function and overall health of the participants to determine the effectiveness and safety of BBP-418 in treating LGMD2I.

    A key aspect being observed is the change from baseline in the North Star Assessment for Limb Girdle Muscular Dystrophy after 36 months of treatment. This will aid in understanding the impact of BBP-418 on muscle function. In addition, the frequency and severity of any treatment-emergent adverse events will be tracked to ensure the medication’s safety over the long term.

    This study is a randomized, placebo-controlled, double-blind study, meaning participants will be randomly assigned to receive either the BBP-418 treatment or a placebo, with neither the participants nor the study staff aware of which group they are in. This approach helps ensure the reliability of the study results.

    DenmarkItalyNetherlandsNorwayUnited Kingdom
  • Exploring EDG-5506 for Becker Muscular Dystrophy

    The GRAND CANYON study is part of a larger research effort to explore the potential benefits of a new medication called EDG-5506 for individuals with Becker Muscular Dystrophy. This medication is taken orally, once a day, and comes in different doses. The study aims to understand how safe and effective EDG-5506 is in treating this condition.

    Previously, a segment of this research, known as CANYON, was conducted and has now successfully enrolled all its participants. Building on this, the GRAND CANYON study is currently inviting adults with Becker Muscular Dystrophy to join this next phase. This part of the study is designed to be very thorough, involving a double-blind method where neither the participants nor the researchers know who is receiving the actual medication or a placebo. This approach helps ensure the results are unbiased and reliable.

    Participants in the GRAND CANYON study will be randomly assigned to either receive EDG-5506 or a placebo, with a higher chance of receiving the actual medication. The study spans over an 18-month treatment period, with a 4-week screening phase before the treatment starts and a 4-week follow-up period after the treatment ends.

    The main focus of the study is to monitor any adverse events or side effects from taking the medication, as well as its overall safety. Additionally, the study will look at changes in specific health markers, like serum Creatine Kinase, and functional measures, such as the North Star Ambulatory Assessment scale, to gauge the medication’s effectiveness.

    NetherlandsUnited Kingdom
  • Study on the effectiveness of Givinostat in Non-Walking Duchenne Muscular Dystrophy Patients

    This clinical trial is focused on testing the effectiveness, safety, and how well patients can tolerate a medication called Givinostat for those who have Duchenne Muscular Dystrophy (DMD) and can no longer walk. The study is designed for male pediatric patients aged between 9 to less than 18 years. A total of 138 participants will be involved, and they will be divided into two groups. One group will receive Givinostat, and the other group will receive a placebo, which is a substance with no therapeutic effect, designed to mimic Givinostat. This division will be done randomly and both the patients and the doctors will not know who is receiving the actual medication and who is receiving the placebo, making this a double-blind study.

    The main goal of this study is to see if Givinostat can help reduce muscle decline in patients with DMD who cannot walk, by looking at changes in upper limb function after 18 months of treatment. The safety and tolerability of Givinostat in these patients will also be closely monitored.

    Participants will be involved in the study for about 20 to 21 months, which includes a 4-week screening period to confirm eligibility, 18 months of treatment, and a follow-up period. At the end of the treatment period, all participants, regardless of which group they were in, will have the option to join a long-term safety study where they will receive Givinostat.

    BelgiumFranceGermanyItalyNetherlandsUnited Kingdom
  • Research to enhance cancer treatments for kids and teens

    This clinical trial, known as CAMPFIRE, encompasses several studies testing new drugs for children and young adults with cancer. It includes various drug combinations such as Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel, Abemaciclib, Irinotecan, and Temozolomide. These trials aim to evaluate the safety and effectiveness of these drugs in treating different cancer types. The study is interventional, with an estimated enrollment of 105 participants, randomized in parallel assignment. The primary purpose is treatment-focused.

    BelgiumFranceGermanyItalyNetherlandsSpainUnited Kingdom
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

  • Research on medicine combination for B-cell Non-Hodgkin Lymphoma

    This study is about testing epcoritamab, a new drug for a type of blood cancer called B-cell Non-Hodgkin Lymphoma. The goal is to see if the drug is safe for people and can successfully fight the cancer. Doctors will combine this drug with other medicines that are typically used to treat this cancer. The combined treatment will vary for different groups of patients, depending on factors like their specific type of cancer or their overall health. Some patients will be given epcoritamab on its own, while others will receive it with other cancer medicines. The study has two parts. The first part is to find a safe dose of the drug. The second part is to determine how well this drug helps in treating the cancer. Side effects will be closely monitored during the study.

    BelgiumCzechiaDenmarkFinlandFranceItalyNetherlandsNorwaySpainSwedenUnited Kingdom
  • Investigating safety and efficacy of new drug in spinocerebellar ataxia and Huntington’s disease

    In the search for better treatment options for neurodegenerative diseases like spinocerebellar ataxia and Huntington’s disease (HD), a new drug referred to as VO659 is currently being tested. The main goals are to observe how safe this new medicine is for patients and understand how it behaves in the body (this is often called pharmacokinetics). In this trial, patients who can still walk and have mild to moderate spinocerebellar ataxia or early Huntington’s disease will receive up to five doses of VO659. The application of the drug is not oral; instead, it will be administered via injections into the lower spine. It’s important to understand that the entire process will last for about 42 weeks per patient, consisting of initial screening, dosing, and post-dosing stages. All throughout the trial, suitable samples will be collected to monitor safety and drug responses.

  • Evaluating datopotamab deruxtecan & pembrolizumab for advanced lung cancer

    This study compares two treatments for people with a type of lung cancer called ‘non-small cell lung cancer’ that has spread to other parts of the body. It tests whether combining a drug called datopotamab deruxtecan (Dato-DXd) with pembrolizumab works better than using pembrolizumab alone. Aimed at patients with non-small cell lung cancer (NSCLC) who haven’t had previous systemic therapy, it’s especially for those with high PD-L1 tumor expression.

    AustriaBelgiumFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Comparison of drug combinations in the treatment of advanced lung cancer

    This trial studies a first-line treatment involving Dato-DXd plus pembrolizumab compared to pembrolizumab alone in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations. The goal is to evaluate the effectiveness and safety of this combined strategy. Target volunteers must not have received any treatments for their advanced or metastatic NSCLC. Participation includes receiving either the combined treatment or pembrolizumab alone. Regular health checks will monitor if any changes or adverse events occur during the trial.

    AustriaBelgiumFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Examining new drug combo vs. standard treatment with pembrolizumab for advanced lung cancer

    This trial is examining if a combination of two medications, Dato-DXd and pembrolizumab, could be superior to using pembrolizumab alone in treating a type of lung cancer known as metastatic non-small cell lung cancer (NSCLC). Participants will include those who have advanced or spread NSCLC and haven’t had systemic treatment for it. The team will be comparing whether the combination treatment can help patients live longer or keep the cancer from growing for a longer period. One group of participants will get pembrolizumab on its own, while another will get both Dato-DXd and pembrolizumab. An important part of the study will assess how the treatment affects the patient’s symptoms and quality of life.

    AustriaBelgiumFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Colorectal surgery study: testing a cancer-highlighting dye

    A study is underway to test a new imaging dye called SGM-101 in patients having surgery for colorectal cancer. This dye might help doctors see cancer better during surgery when used with a special light. The study will compare surgeries done with the new dye and light to those done in the usual way. The goal is to make sure the new method is safe and helps doctors remove all the cancer. Adults scheduled for certain types of colorectal surgery can join this study.

  • Testing new medication for safety and effect on Huntington’s disease

    This clinical trial evaluates the safety and efficacy of PTC518, a medication for Huntington’s Disease. The study involves adults with genetically confirmed Huntington’s Disease, receiving either PTC518 or a placebo. Over 12 months, the trial will monitor changes in symptoms and any adverse effects. The goal is to understand if PTC518 can safely and effectively manage Huntington’s Disease symptoms, potentially offering a new treatment option for those affected by this neurodegenerative disorder.

    AustriaFranceGermanyItalyNetherlandsSpainUnited Kingdom
  • Studying rilvegostomig in the treatment of advanced or metastatic lung cancer

    This clinical trial evaluates rilvegostomig, a new drug for advanced non-small cell lung cancer (NSCLC). The study involves people with stage III or IV NSCLC and explores if rilvegostomig is safe and effective. It’s conducted in several parts, including dose escalation and expansion, to determine the best dose and its impact on the cancer. The trial measures how patients respond to the treatment and monitors for any side effects.

  • Comparing Imlifidase with standard treatment in anti-glomerular basement membrane disease

    This clinical trial is testing a medication called Imlifidase in patients who have a serious disease called anti-GBM (Goodpasture syndrome). The researchers are doing this study to compare two groups: people who take Imlifidase along with the usual treatment, and people who only get the usual treatment. This typical treatment consists of plasma exchange (PLEX), Cyclophosphamide and glucocorticoids. This study will last for 2 years. Researchers will measure things like kidney function, levels of harmful anti-GBM antibodies, breathing symptoms, drug interaction and patients’ quality of life.

    CzechiaDenmarkFranceGermanyItalyNetherlandsSpainSwedenUnited Kingdom
  • Evaluation of Namilumab in Chronic Pulmonary Sarcoidosis

    In this study, the focus is on investigating the potential benefits of the medication Namilumab for individuals with Chronic Pulmonary Sarcoidosis, a lung disease. Following the standard structure of medical studies, the new medicine is compared to a placebo. Monthly injections are administered to all participants for six months, but the allocation of the real medicine or the placebo remains undisclosed. For those who successfully complete the initial phase without significant issues, there is an option to extend their participation for an additional 28 weeks. During this extended period, the participants will continue to receive the actual medication, allowing for the monitoring of their progress and the assessment of the medicine’s impact over a more extended duration.

    BelgiumFranceGermanyNetherlandsUnited Kingdom
  • Examining ultrasound-assisted and standard treatment for lung clots

    In this study, researchers want to compare two treatments for a disease called pulmonary embolism. This is a disease in which a blood clot blocks the vessels that supply blood to the lungs. The group of people taking part in the study will be randomly assigned to receive either blood-thinning medications alone (anticoagulation) or blood-thinning medications using a blood clot-dissolving device. The name of this device is the EkoSonic endovascular device. The research will continue for 12 months, and the health of the participants will be regularly monitored.

    AustriaFranceGermanyNetherlandsPolandUnited Kingdom
  • Inhalation therapy study for Alpha-1 Antitrypsin deficiency

    The aim of this study is to find out how effective and safe a drug called “Kamada-AAT for inhalation” is for people suffering from a disease called Alpha 1-Antitrypsin Deficiency. In this condition, people have lower than normal levels of a protein called alpha-1 antitrypsin, which can cause breathing problems. The goal is to see if inhaling this medication can help people suffering from moderate to severe breathing problems caused by alpha-1-antitrypsin deficiency. Participants will practice using a device called a saline nebulizer before being given the real drug or a placebo that looks identical. After using the drug or placebo daily for two years, doctors will continue to monitor the patient’s health for another six months.

    BelgiumFinlandNetherlandsSwedenUnited Kingdom
  • Long-term safety of efgartigimod in myasthenia gravis

    The purpose of this trial is to assess the long-term safety of efgartigimod, both intravenously and subcutaneously, in individuals who participated in the previous studies (ARGX-113-2006 and ARGX-113-2207) for generalized myasthenia gravis (gMG). The goal is to ensure the ongoing safety of the drug over an extended period and to monitor any potential side effects.

    BelgiumNetherlandsPolandUnited Kingdom
  • Study on new drug’s effect on growing desmoid tumors

    This research is about the effect of a medication named AL102 on Desmoid tumors that continue to grow worse. The study is in 2 phases. In phase 1, every patient will receive AL102, and researchers will determine the ideal dosage of the drug. In phase 2, some of those patients will receive AL102 while others will get a substance without any medicine in it (a placebo). The study aims to provide new insights and potentially a new treatment option for this condition.

    BelgiumGermanyItalyNetherlandsPolandSpainUnited Kingdom

See more clinical trials in other cities in Netherlands: